Skip to content
Precision for Medicine

Announcing the Institute@Precision, a Collaborative Forum for Biopharma Innovation.

AdobeStock_183200379 AdobeStock_183200379

Clinical Trial Management Services

Execute your trials with Precision: Unrivaled Clinical Trial Management for global impact
Empower your clinical research with Precision for Medicine's bespoke Clinical Trial Management Services. Our approach seamlessly blends innovation in early-phase trials with robust effectiveness in late phases, ensuring your research advances confidently towards its goals. With an unwavering commitment to excellence, we propel the advancement of life-changing therapies for patients in need around the globe.

End-to-end Clinical Trial Management services

Precision for Medicine's end-to-end capabilities unite expert teams and global reach with advanced processes and technologies. By transforming complex data into actionable insights, we not only navigate the intricacies of each phase but also empower each trial with the agility and insight needed to drive success from concept to conclusion. Our strategic and collaborative approach to clinical trial management services accelerates trial success, setting new industry standards.

CRO Leadership Awards 2024

Award-winning clinical trial management services

Precision for Medicine's receipt of the 2024 CRO Leadership Awards in every category signifies more than our excellence; it highlights our partnership's value in propelling your clinical trials forward. Our award-winning expertise delivers not just superior trial management but a shared mission in bringing transformative therapies to patients globally.

See how our consistent recognition in the industry underscores our commitment to excellence in clinical trial management.

3500 Experts fueling innovation
600 Global trials driving progress
20 Years of clinical excellence

Advancing outcomes at every stage

  • Discover Early Phase Excellence
    clinical trial patient doctor

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.

    Explore
  • Discover Late Phase Success
    patient on bed clinical

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, compliance, and efficiency for your clinical journey.

    Explore

Deep experience with debilitating disease and unique modalities

Like you, we understand that there’s a patient throughout the development pathway. Supporting our partners to bring innovative treatments to patients is our purpose. Leverage our experience in these therapeutic areas.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO Services

    A recognized leader in oncology and rare diseases with rich experience in complex trials

    Explore
  • Discover Explore
    specialty-lab-services

    Laboratory
    Services

    Experts in translational and biomarker sciences with worldwide specialty labs and central lab services that are enabling breakthroughs.

    Explore

Read our latest Precision insights

Stay updated with the latest insights in statistical programming and automation through our blog. 

Read: Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

Lost in Translation: Turning Multi-omic Chaos into Clinical Clarity

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=159488778872, hs_child_table_id=0, hs_updated_at=1744653337128, hs_published_at=1762810487482, description=Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Darren%20Davis.webp',altText='Darren Davis',fileId=165891429693}, linkedin=https://www.linkedin.com/in/drdarrendavis, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Davis, PhD, hs_initial_published_at=1762810487559, hs_created_at=1709645745103, hs_is_edited=false, hs_deleted_at=0, name=Darren, job=Senior Vice President, Translational Sciences, slug=darren-davis, email=, hs_updated_by_user_id=26433386}, second={hs_id=167888548278, hs_child_table_id=0, hs_updated_at=1722451546286, hs_published_at=1762810487482, description=Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Deb%20Phippard.webp',altText='Deb Phippard',fileId=165892372605}, linkedin=https://www.linkedin.com/in/deb-phippard-103b54, team=[{id=163072475009, name='Translational Sciences Leadership'}], hs_name=, hs_path=, lastname=Phippard, PhD, hs_initial_published_at=1716194887110, hs_created_by_user_id=2737751, hs_created_at=1716194842710, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Chief Scientific Officer, slug=deborah-phippard-translational-sciences, email=, hs_updated_by_user_id=26433386}, third={hs_id=159488778883, hs_child_table_id=0, hs_updated_at=1762803857448, hs_published_at=1762810487482, description=Jie Yang, PhD is a Scientific Liaison for Precision for Medicine. An Immunologist by training with extensive industry expertise in designing translational assays for biomarker-guided clinical trials. Conducted postdoctoral research on immuno-oncology at MD Anderson Cancer Center. Led biomarker assay development and collaborated on the implementation of new technologies for pre-clinical and clinical studies conducted by pharmaceutical and biotech companies for drug development., avatar=Image{width=885,height=886,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Jie-Yang.png',altText='Jie-Yang',fileId=167372215352}, linkedin=https://www.linkedin.com/in/jie-yang-0528221b, hs_name=, hs_path=, lastname=Yang, PhD, hs_initial_published_at=1762810487559, hs_created_at=1709645745114, hs_is_edited=false, hs_deleted_at=0, name=Jie, job=, slug=jie-yang, email=, hs_updated_by_user_id=26433386}})
  • Darren D. avatar Deborah P. avatar Jie Y. avatar
  • Darren D.

    Deborah P.

    Jie Y.

Discover
Read: Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

Biomarkers

Biomarker-Driven Clinical Trials in Oncology: Enrichment, Stratification, All-Comers & Basket

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199138167916, hs_child_table_id=0, hs_updated_at=1762375981786, hs_published_at=1762810487482, avatar=Image{width=800,height=800,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Paul%20Steven.png',altText='Paul Steven',fileId=199144298570}, lastname=Steven, hs_initial_published_at=1762375986271, hs_created_by_user_id=26433386, hs_created_at=1762375951865, hs_is_edited=false, hs_deleted_at=0, name=Paul, job=Principal Biostatistician, slug=paul-steven, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Paul Steven avatar

    Paul Steven

Discover
Read: Investor Relations, Clinical Operations, and the Future of Biotech Financing Investor Relations, Clinical Operations, and the Future of Biotech Financing

Clinical Trials - Translational Research - Early Phase Research

Investor Relations, Clinical Operations, and the Future of Biotech Financing

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548862, hs_child_table_id=0, hs_updated_at=1716454315513, hs_published_at=1762810487482, description=Teresa is a respected business development strategist, building successful clinical programs for clients in Massachusetts. She is an innovator of fresh approaches to biomarker planning, translational solutions, and clinical study design. Her experience spans the execution of Phase 1-4 clinical trials, specialty lab services, companion and in vitro diagnostic strategies, and biomarker data management., avatar=Image{width=700,height=700,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Teresa-Pokladowski-300x300.png',altText='Teresa-Pokladowski-300x300',fileId=168135942975}, linkedin=https://www.linkedin.com/in/teresapokladowski/, lastname=Pokladowski, hs_initial_published_at=1713363230550, hs_created_by_user_id=5166971, hs_created_at=1713362443509, hs_is_edited=false, hs_deleted_at=0, name=Teresa, job=Regional Vice President, Clinical Business Solutions, North America, slug=teresa-pokladowski, hs_updated_by_user_id=26433386}, second={hs_id=197608580658, hs_child_table_id=0, hs_updated_at=1760465121471, hs_published_at=1762810487482, description=Hannah Dereseiwicz is a strategic force in investor relations, helping biotech innovators translate complex science into compelling narratives that drive engagement and growth. With a track record spanning commercial launches, M&A activity, and high-stakes communications, she brings clarity, confidence, and momentum to every stage of a company’s journey. Hannah’s approach is defined by the three A’s—ambitious, approachable, and authentic—making her a trusted partner for teams looking to elevate their story and connect with the audiences that matter most., avatar=Image{width=636,height=476,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Hannah%20Deresiewicz.webp',altText='Hannah Deresiewicz',fileId=197608718507}, lastname=Deresiewicz, hs_initial_published_at=1760465283803, hs_created_by_user_id=26433386, hs_created_at=1760464991513, hs_is_edited=false, hs_deleted_at=0, name=Hannah, job=Executive Vice President, Managing Director Precision AQ – Investor Relations & External Communications, slug=hannah-deresiewicz, hs_updated_by_user_id=26433386}, third={}})
  • Teresa P. avatar

    Teresa P.

  • Hannah D. avatar

    Hannah D.

Discover